Biocon arm Syngene InternationalThe 10-year-old agreement has been signed to produce the drug substance for Librela (a monoclonal antibody that treats osteoarthritis in dogs) with Zoetis, a US-based animal welfare company.
In 2011, Zoetis began a collaboration. Over the last 11 years, Syngene developed monoclonal antibody treatments for animal health. This includes developing and manufacturing clinical supplies for a treatment for allergic dermatitis or atopic dermatitis.
“This agreement, initially centred on Librela, paves the way for development and manufacturing of other molecules in the coming years and is expected to be worth up to $ 500 million to Syngene over 10 years, subject to regulatory approvals and market demand,” the company said on Thursday.
Librela or bedinvetmab, has already been launched in Europe and the UK, and won ‘Best new companion animal product’ by IHS Markit Connect in 2021 for its transformational impact on pain relief for canines.
Managing director and chief executive officer, Syngene International, Jonathan Hunt said: “We are delighted to be expanding our partnership with Zoetis. This multi-year deal marks a turning point for our Development and Manufacturing Services Division and I look forward to completing all the regulatory inspections. This 10-year agreement will position Syngene as a leading Contract Development and Manufacturing Organisation (CDMO) in animal health globally.”
“By advancing the next stage of Librela with Syngene, we continue to build a strong global supply network for Zoetis products and fulfill our purpose to nurture the world and humankind by advancing care for animal,” said Nick Ashton, executive vice president and president, global manufacturing and supply, Zoetis Inc.
Zoetis, a $7.8 billion animal health company has a large pipeline of medicines, diagnostics and vaccines.
Syngene on the other side does drug discovery work at all stages, including pre-clinical and clinical development. They also offer manufacturing services to their clients. This includes industries like pharmaceutical, biotech and nutrition as well as speciality chemicals.
Syngene clients make up around 74%.
“The global market for contract research was valued at $48.55 billion in 2020 and is expected to reach $83.34 billion growing at a CAGR of 9.4 per cent. Within this, the outsourcing market for drug discovery and early development services is expected to grow at a CAGR of 6.4 per cent over 2020-2026 to reach a value of $44 billion by the end of this period,” the company noted in its FY22 annual report.
Hunt, in the company’s annual report, stated that Syngene expecting strong demand for both biologics development and biologics manufacturing capacity.
“Recent investments in expanding both our mammalian and microbial facilities will put us into a strong position to capture some of that demand,” he added.